Suven Life Sciences Limited SUVEN NSEPHARMA
Company Overview
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer's disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathic hypersomnia. The company also develops Ropanicant (SUVN-911), an a4ß2 nicotinic acetylcholine receptor (nAChR) antagonist for the treatment of major depressive disorder; Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for management of cognitive dysfunction; and Tenaclidine (SUVN-I6107), a muscarinic M1 positive allosteric modulator for the treatment of cognitive disorders and schizophrenia. In addition, it is involved in the development of programs, such as SUVN-M8036 Serotonin/Dopamine Modulator for psychiatric disorder indications; SUVN-D1044 5-HT4 Agonist for gastrointestinal disorders; M4 PAM for psychosis indications; P2X7 Antagonist for pain and inflammation indications; Multimodal Dual 5-HT2A Antagonist and 5-HT1A Agonist for psychosis and depression indications; 5-HT1A Agonist for treatment resistant depression; Multimodal Dual 5-HT2A Antagonist and SRI for bipolar disorders, and depression and schizophrenia; and M1 PAM for gastrointestinal disorder indications. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited.
Recent Developments
- Mar 2026 Revenue of ₹7.11 Cr (+6.9% YoY); net profit ₹-276.34 Cr.
- Trailing 12 Months Year-on-year growth — revenue +91.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -19.3%, profit CAGR -44.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -19.30% |
| 1 Year: | 91.00% |
Compounded Profit Growth
| 5 Years: | -44.55% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +15.01% |
| 6 Months: | +22.69% |
| 3 Months: | -15.13% |
| 1 Month: | -20.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)29.39 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -19.3% CAGR over 5 years.
- Earnings shrank at -44.6% CAGR over 5 years.
- Trading 31.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SUVEN Suven Life Sciences Limited NSEPHARMA | 268.20 | -18.01 | ₹7,578.33 Cr | 0.00% | -45.62% | -46.73% | -19.30% | -44.55% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,758.00 | 34.88 | ₹4.22 L Cr | 0.91% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,162.00 | 83.32 | ₹2.43 L Cr | 0.32% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,615.30 | 73.73 | ₹1.76 L Cr | 0.81% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,135.00 | 25.30 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 634.25 | 165.17 | ₹1.10 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 7,604.50 | 52.35 | ₹1.09 L Cr | 0.25% | 19.20% | 20.48% | 14.85% | 33.34% |
| 8 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 2,002.50 | 98.99 | ₹1.08 L Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
| 9 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,330.90 | 31.92 | ₹1.08 L Cr | 0.99% | 14.86% | 11.27% | 7.23% | 11.45% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00 Cr | 4.00 Cr | 3.00 Cr | 2.00 Cr | 2.00 Cr | 1.00 Cr | 3.00 Cr | - | 1.47 Cr | 1.87 Cr | 91.92 L | 2.81 Cr | 1.52 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | 1.47 Cr | 1.87 Cr | 91.92 L | 2.81 Cr | 1.52 Cr |
| Operating Expenses | 34.00 Cr | 32.00 Cr | 27.00 Cr | 49.00 Cr | 33.00 Cr | 32.00 Cr | 55.00 Cr | - | 46.63 Cr | 53.98 Cr | 82.01 Cr | 107.50 Cr | 53.74 Cr |
| Operating Income | -34.00 Cr | -30.00 Cr | -26.00 Cr | -48.00 Cr | -32.00 Cr | -32.00 Cr | -53.00 Cr | - | -45.17 Cr | -52.12 Cr | -81.09 Cr | -104.70 Cr | -52.22 Cr |
| EBITDA | -32.00 Cr | -28.00 Cr | -24.00 Cr | -46.00 Cr | -30.00 Cr | -31.00 Cr | -52.00 Cr | - | -42.60 Cr | -50.15 Cr | -75.99 Cr | -100.58 Cr | -43.86 Cr |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 15.78 L |
| Pretax Income | -28.00 Cr | -24.00 Cr | -13.00 Cr | -42.00 Cr | -28.00 Cr | -28.00 Cr | -50.00 Cr | - | -43.94 Cr | -51.52 Cr | -77.31 Cr | -101.92 Cr | -45.60 Cr |
| Tax Provision | -0 | -0 | -0 | -0 | 1.12 Cr | -0 | -0 | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -28.00 Cr | -24.00 Cr | -13.00 Cr | -42.00 Cr | -27.00 Cr | -28.00 Cr | -50.00 Cr | - | -43.94 Cr | -51.52 Cr | -77.31 Cr | -101.92 Cr | -45.60 Cr |
| Diluted EPS | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | - | -2.02 | -2.36 | -3.48 | -4.55 | -2.02 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 521.00 Cr | 499.00 Cr | 543.00 Cr | 625.00 Cr | 286.00 Cr | 13.00 Cr | 13.00 Cr | - | 13.54 Cr | 11.69 Cr | 6.66 Cr | 7.11 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 36.78 L | 71.79 L | 1.04 Cr | 98.84 L |
| Gross Profit | - | - | - | - | - | - | - | - | 13.17 Cr | 10.98 Cr | 5.62 Cr | 6.13 Cr |
| Operating Expenses | 361.00 Cr | 398.00 Cr | 414.00 Cr | 427.00 Cr | 300.00 Cr | 128.00 Cr | 93.00 Cr | - | 145.09 Cr | 145.27 Cr | 176.87 Cr | 295.85 Cr |
| Operating Income | 147.00 Cr | 84.00 Cr | 108.00 Cr | 177.00 Cr | -25.00 Cr | -120.00 Cr | -84.00 Cr | - | -131.92 Cr | -134.30 Cr | -171.25 Cr | -289.73 Cr |
| EBITDA | 159.00 Cr | 102.00 Cr | 129.00 Cr | 198.00 Cr | -14.00 Cr | -116.00 Cr | -80.00 Cr | - | -111.44 Cr | -99.42 Cr | -154.88 Cr | -270.57 Cr |
| Interest Expense | 5.00 Cr | 6.00 Cr | 6.00 Cr | 5.00 Cr | 2.00 Cr | 1.00 Cr | 1.00 Cr | - | 28.92 L | 15.84 L | 4.66 L | 15.78 L |
| Pretax Income | 152.00 Cr | 98.00 Cr | 123.00 Cr | 196.00 Cr | 0 | -106.00 Cr | -77.00 Cr | - | -118.27 Cr | -106.08 Cr | -160.75 Cr | -276.34 Cr |
| Tax Provision | 42.56 Cr | 25.48 Cr | 35.67 Cr | 72.52 Cr | 0 | 11.66 Cr | 5.39 Cr | - | 0 | -1.00 Cr | 0 | 0 |
| Net Income | 109.00 Cr | 72.00 Cr | 87.00 Cr | 124.00 Cr | -24.00 Cr | -94.00 Cr | -72.00 Cr | - | -118.27 Cr | -105.08 Cr | -160.75 Cr | -276.34 Cr |
| Diluted EPS | 5.70 | 3.76 | 4.57 | 6.48 | -1.25 | -4.94 | -3.78 | - | -6.63 | -4.82 | -7.37 | -12.13 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 773.00 Cr | 751.00 Cr | 816.00 Cr | 919.00 Cr | 303.00 Cr | 182.00 Cr | 128.00 Cr | - | 388.91 Cr | 284.90 Cr | 135.18 Cr | 624.21 Cr |
| Current Assets | - | - | - | - | - | - | - | - | 251.59 Cr | 256.67 Cr | 75.47 Cr | 546.71 Cr |
| Cash & Equivalents | - | - | - | - | - | - | - | - | 37.02 Cr | 14.93 Cr | 15.03 Cr | 8.28 Cr |
| Inventory | - | - | - | - | - | - | - | - | 0 | 70.84 L | 23.75 L | 10.20 L |
| Receivables | - | - | - | - | - | - | - | - | 80.74 L | 1.29 Cr | 1.34 Cr | 1.51 Cr |
| Total Liabilities | - | - | - | - | - | - | - | - | 13.59 Cr | 14.86 Cr | 25.20 Cr | 32.81 Cr |
| Current Liabilities | - | - | - | - | - | - | - | - | 11.13 Cr | 13.52 Cr | 23.49 Cr | 18.75 Cr |
| Long Term Debt | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - |
| Total Debt | 109.00 Cr | 83.00 Cr | 71.00 Cr | 34.00 Cr | 3.00 Cr | 6.00 Cr | 5.00 Cr | - | 1.61 Cr | 70.97 L | 0 | 16.69 Cr |
| Total Equity | 560.00 Cr | 596.00 Cr | 667.00 Cr | 768.00 Cr | 239.00 Cr | 144.00 Cr | 108.00 Cr | - | 375.32 Cr | 270.04 Cr | 109.99 Cr | 591.40 Cr |
| Shares Outstanding | - | - | - | - | - | - | - | - | 21.81 Cr | 21.81 Cr | 21.81 Cr | 26.37 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 143.00 Cr | 68.00 Cr | 109.00 Cr | 70.00 Cr | -53.00 Cr | -135.00 Cr | -96.00 Cr | - | -115.98 Cr | -82.62 Cr | -154.10 Cr | -301.41 Cr |
| Investing Cash Flow | -110.00 Cr | -39.00 Cr | -311.00 Cr | -1.00 Cr | 30.00 Cr | 146.00 Cr | 56.00 Cr | - | -247.81 Cr | 61.59 Cr | 154.95 Cr | -462.11 Cr |
| Financing Cash Flow | 179.00 Cr | -68.00 Cr | -30.00 Cr | -52.00 Cr | 5.00 Cr | 3.00 Cr | 35.00 Cr | - | 395.54 Cr | -1.05 Cr | -75.63 L | 756.78 Cr |
| Capital Expenditure | -118.00 Cr | -58.00 Cr | -30.00 Cr | -42.00 Cr | -39.00 Cr | -2.00 Cr | -6.00 Cr | -19.77 Cr | -2.89 Cr | - | -37.28 Cr | -5.08 Cr |
| Free Cash Flow | 25.00 Cr | 10.00 Cr | 79.00 Cr | 28.00 Cr | -92.00 Cr | -137.00 Cr | -102.00 Cr | - | -118.88 Cr | -82.62 Cr | -191.38 Cr | -306.50 Cr |
| Net Change in Cash | 212.00 Cr | -39.00 Cr | -232.00 Cr | 17.00 Cr | -18.00 Cr | 14.00 Cr | -5.00 Cr | - | 31.75 Cr | -22.09 Cr | 9.32 L | -6.75 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 97.3% | 93.9% | 84.4% | 86.1% |
| Operating Margin % | 28.2% | 16.8% | 19.9% | 28.3% | -8.7% | -923.1% | -646.2% | - | -974.3% | -1,148.5% | -2,572.9% | -4,072.2% |
| Net Margin % | 20.9% | 14.4% | 16.0% | 19.8% | -8.4% | -723.1% | -553.8% | - | -873.5% | -898.6% | -2,415.1% | -3,884.1% |
| ROE % | 19.5% | 12.1% | 13.0% | 16.1% | -10.0% | -65.3% | -66.7% | - | -31.5% | -38.9% | -146.1% | -46.7% |
| ROCE % | - | - | - | - | - | - | - | - | -34.9% | -49.5% | -153.3% | -47.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SUVEN
Market Trading Guide: Suven Life Sciences among 2 stock recommendations for Friday - The Economic Times
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxOUVFpQ01aSHZMNVpRUldGR29JZUM2dGV1a1NXdEI5NVNQZ1FVdkVXTURJWG1Ea2VzOE9Mei1ES3daVm9QMER6OVl6RHpudGdpUTVQdTB5MEluOFNwZkRWWEF1bUpDVVQ0V2JIUjJHcG5xbDZzNDV4UkdyRDY2bFBQQTVHVDBkY1p5Yk1pel…
SUVEN LIFE SCIENCES : FORENSIC DEEP DIVE - YouTube
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1sOS1KRnpQZ0w0LWRHRTZFNmd5OHpsbFpwOUV3MlRJaEZnSUVGWFdjdWh5UHlGOThGRkdVWDNBRGdpTkpNemhKM2MtQlYyd2xxOFdleUxCMnRPMFhU?oc=5" target="_blank">SUVEN LIFE SCIENCES : FORENSIC DEEP DIVE</a…
Suven Life Sciences Shares Decline Over 5% As Q1 Net Loss Widens To Rs 128 Crore - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNMnVDWW9JZFZLdHU3SjJxb2lzRW4wS09IREp0WG9OUVpkMzBxVVI1QkVuUmE1N2NVdGlaNXRYMk9zRDZOYlVTWGdoMUtVS2dJS0liTjZqY2tqOXZzQTF4NDFXUGN3Zk1XYzk5Qnc4VDcydU9Ba2xNX3pFelBQcTBGZ1VmTUVWMUZoOUhBST…
Suven Life Sciences (NSE:SUVEN): What Is the Special Window for Re-Lodgment of Physical Share Transfers? - Kalkine India
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPMzhGakFpQW5xa1N5bHhzVHk5UTAzUTdYNmhrWnVNQkM3UWxVdU0yS0RjYWFYekJBakdpRW1oTzl0RFhPSFdvVzAxRGJNQXAtanNqN0w4dWNIWTM4S0NuME04SWpRMW1oTlJmVW13czczV210QUtWbzIzYTRvMlZwUWhacThHakhrdjROZj…
Here's Why We're Not Too Worried About Suven Life Sciences' (NSE:SUVEN) Cash Burn Situation - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPRUhtaENZSmVLVzdLVERBQjdUYm8xT0dXVXREN0RNYTNvdkgzN0xoaWRqNWRxSlBTaE5VaXVTT2E4SVlIal9kQy1qVFpwN1NOa1B5ajFkX3Z3ZXBBYjhhd3JHWVU2bVp3b0wxbmhqLUxxdGE2V05leFJuU1FneWw2S3lWbWptbVJBLUNZX2…
Suven Life Sciences Ltd. Share Price at Fresh 52-Week High - Univest
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPUWdqOE5QWVRWdDEyMlFkVHBfeXQ0SnAyRXdZaWdGSEIzMnBkTGhxeFJjUHE0b1hPUW1WUTFOUUVLVmhZRzVDZnNrR1dfckpENnlnM3lRWkh0Q2x5UmRnY1p4N2hZRWN2VDY3eFRLUlZlbGU2bDJWand5ZFVnaHZpZnJwY3NueWQzeG1MMU…
SUVEN — Frequently Asked Questions
What is the current share price of Suven Life Sciences Limited (SUVEN)?
As of 2026-10-24 04:55 IST, Suven Life Sciences Limited (SUVEN) trades at ₹268.20 on NSE. Its 52-week range is ₹126.65 to ₹392.05.
What is the market capitalisation of SUVEN?
Suven Life Sciences Limited (SUVEN) has a market capitalisation of ₹7,578.33 Cr on NSE.
What is the P/E ratio of SUVEN?
SUVEN trades at a trailing price-to-earnings (P/E) ratio of -18.01. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 12.61.
What is the return on equity (ROE) of SUVEN?
SUVEN has a return on equity (ROE) of -46.73%. Its return on capital employed (ROCE) is -45.62%.
Is SUVEN a good stock to buy?
This page provides a data-driven analysis of Suven Life Sciences Limited (SUVEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.